Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405405 · ClinicalTrials.gov registry record · Phase 1
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00405405 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 13 participants.
The verdict
NCT00405405, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
- DRUG Cisplatin
- RADIATION Radiotherapy
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405405
The ClinicalTrials.gov registry entry for NCT00405405 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00405405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00405405 about?
NCT00405405 is a clinical study titled "Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer". To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer
What is the current status of trial NCT00405405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2006-12. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00405405?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG), Cisplatin (DRUG), Radiotherapy (RADIATION), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00405405?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.